Moderna said on Thursday it had paused its plans to build a vaccine manufacturing facility in Kenya, following a post-pandemic decline in demand for COVID-19 vaccines. The move is in line with Moderna's strategy of resizing its manufacturing network to cut costs, even as it aims to spend around $4.5 billion this year in research and development of several new vaccines, including for cancer and respiratory syncytial virus (RSV). Source: Reuters 12/4/2024